{"id":1017017,"date":"2026-11-05T02:52:26","date_gmt":"2026-11-05T07:52:26","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/dianthus-therapeutics-highlights-recent-business-achievements-and-reports-q3-2026-financial-results\/"},"modified":"2026-11-05T02:52:26","modified_gmt":"2026-11-05T07:52:26","slug":"dianthus-therapeutics-highlights-recent-business-achievements-and-reports-q3-2026-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dianthus-therapeutics-highlights-recent-business-achievements-and-reports-q3-2026-financial-results\/","title":{"rendered":"Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 2026 Financial Results"},"content":{"rendered":"
\n

\n Advancing a neuromuscular franchise with claseprubart, a highly potent, investigational classical pathway inhibitor, with best-in-disease potential across generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN)<\/em>\n <\/p>\n

\n Phase 3 EMERGE registrational trial of claseprubart in gMG evaluating 300mg\/2mL Q2W and 300mg\/2mL Q4W on track, with top-line results expected in 2H\u201928 <\/em>\n <\/p>\n

\n Phase 3 CAPTIVATE trial of claseprubart in CIDP evaluating 300mg\/2mL Q2W now conservatively projected to require less than 200 participants in the open-label Part A in order to randomize 128 responders into the placebo-controlled withdrawal Part B portion of the study, with Part A top-line results expected by YE\u201927 and Part B top-line results expected by YE\u201928<\/em>\n <\/p>\n

\n Phase 2 MoMeNtum trial of claseprubart in MMN top-line results on track for December \u201926<\/em>\n <\/p>\n

\n DNTH212 continues to advance with Phase 1 single ascending dose (SAD) Part A healthy volunteer preliminary data expected in Q1\u201927. First SLE patient in Part B of the Phase 1 SAD study was dosed in October, with preliminary results from Part B expected in 2H\u201927. The Dianthus-led Phase 1 multiple ascending dose (MAD) study is planned to initiate in Q2\u201927 with preliminary data expected in 2H\u201927<\/em>\n <\/p>\n

\n DNTH312, an internally developed, first-in-class, next-generation bifunctional fusion protein combining claseprubart and TACI to target potent inhibition of aC1s and BAFF\/APRIL for severe autoimmune diseases, on track to be Phase 1 ready by YE\u201927<\/em>\n <\/p>\n

\n Approximately $1.2 billion of cash as of September 30, 2026 provides expected runway into 2030<\/em>\n <\/p>\n

NEW YORK and WALTHAM, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) — Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today reported financial results for the third quarter ending September 30, 2026, and provided an update on other recent business achievements.<\/p>\n

\u201cThe Dianthus team continues to execute on our strategy to build a best-in-disease neuromuscular franchise with claseprubart across gMG, CIDP, and MMN, while advancing an exciting pipeline of potentially best-in-disease bifunctional fusion proteins with DNTH212 and DNTH312,\u201d said Marino Garcia, Chief Executive Officer of Dianthus Therapeutics. \u201cFollowing top-line results from our Phase 2 MoMeNtum trial of claseprubart in December, we plan to quickly initiate a Phase 3 trial in MMN in 2027. MMN represents a significant market opportunity, characterized by high unmet needs and limited competition. IVIg is the only approved treatment for patients with MMN, and the lack of patient and physician satisfaction with IVIg presents a meaningful opportunity for claseprubart, given its unique potential for a differentiated, best-in-disease profile due to potent inhibition of the classical pathway and preservation of the lectin and alternative pathways while targeting a patient-friendly, 300mg\/2mL, self-administered subcutaneous autoinjector once every two weeks.\u201d<\/p>\n

\n
\n Claseprubart: Potential Best-in-Disease aC1s Inhibitor for Neuromuscular Diseases <\/u>
\n <\/strong>\n <\/p>\n

Claseprubart is an investigational, clinical-stage, potent monoclonal antibody engineered to selectively target the classical pathway by inhibiting only the active form of the C1s protein, a clinically validated complement target. Claseprubart is designed to enable a more convenient, subcutaneous (S.C.), self-administered injection dosed as infrequently as once every two or four weeks. Claseprubart has the potential to be a best-in-disease pipeline-in-a-product across a range of autoimmune disorders with high unmet need.<\/p>\n

\n Generalized Myasthenia Gravis (gMG)<\/strong>\n <\/p>\n